← brief for 2026-08-21 · Slowing decline

From kidney to liver: Are sodium-glucose cotransporter-2 inhibitors emerging as metabolic disease modifiers?

Key takeaways

A study of 100 patients with diabetic kidney disease found that combining finerenone with an SGLT2 inhibitor reduced proteinuria (protein in urine) more than using two different types of SGLT2 inhibitors. The study was small: 100 patients, and lasted 6 months.

Who did this work

Mpisa S · Soldera J

Source

Article · PubMed, the drug frontier · 2026 Sep 25
https://pubmed.ncbi.nlm.nih.gov/42626005/